Contineum Therapeutics Reports $14.5 Million Net Loss in Q1 2026, Decreases Operating Expenses

Contineum Therapeutics, Inc. reported a net loss of $14.5 million for the first quarter of 2026, a decrease from the $16.0 million loss recorded in the same period of 2025. The company's total operating expenses for the quarter were $16.9 million, down from $18.1 million year-over-year. This reduction was primarily driven by a $2.1 million decrease in research and development expenses, which fell to $11.6 million, reflecting lower costs associated with completed clinical trials. General and administrative expenses increased by $0.9 million to $5.3 million, attributed to higher stock-based compensation and personnel-related costs.

As of March 31, 2026, Contineum's total assets amounted to $261.3 million, a decline from $276.6 million at the end of 2025. The decrease in assets was largely due to a significant reduction in cash and cash equivalents, which fell from $75.6 million to $20.2 million. However, the company maintained a strong position in marketable securities, which increased to $226.2 million from $187.3 million. The total liabilities also decreased to $11.3 million from $15.7 million, reflecting a reduction in accrued expenses and operating lease liabilities.

In terms of strategic developments, Contineum has made significant progress in its clinical programs. The company is advancing its lead drug candidates, PIPE-791 and PIPE-307, with ongoing clinical trials. PIPE-791 is being evaluated for idiopathic pulmonary fibrosis and chronic pain, while PIPE-307 is in development for multiple sclerosis and depression. The company has partnered with Johnson & Johnson for the development of PIPE-307, which includes a potential Phase 3 trial. As of March 31, 2026, Contineum had cash, cash equivalents, and marketable securities totaling $246.3 million, which management believes will support operations for at least the next 12 months.

Operationally, Contineum's employee headcount has increased, reflecting its commitment to expanding research and development capabilities. The company has also entered into an amended at-the-market sales agreement, allowing it to sell up to $100 million in shares of its Class A common stock, although no shares were sold under this agreement during the first quarter of 2026. The company continues to explore additional financing options to support its clinical development and operational needs, emphasizing the importance of securing funding to avoid delays in product development.

Looking ahead, Contineum anticipates that its operating expenses will increase as it continues to develop its drug candidates and expand its operations. The company remains focused on advancing its clinical trials and securing regulatory approvals, while also managing its financial resources carefully. The outlook remains cautious, as the company acknowledges the inherent risks and uncertainties associated with drug development and the need for additional funding to sustain its growth trajectory.